A Senior VP of a Bay Area cancer biotech's R&D recently gave a spin to an old saying and commented, “the beatings will continue until the patient body's morale will improve,” and he added, “the beating will now come through cancer cell metabolism."
Showing posts with label agios. Show all posts
Showing posts with label agios. Show all posts
Monday, October 31, 2011
Thursday, December 16, 2010
Emerging Target, “Cell Metabolism”: From Boondocks to Harvard Square, Boston
The emergence of “cancer energy metabolism” as one of the promising targets, is affirmed by the two significant Pharma deals this year:
Labels:
2DG,
agios,
cancer metabolism,
cancer target,
celgene,
cornerstone pharma,
CPI-613,
drug discovery,
IDH1,
LDH-A,
MCT1,
PKM2,
warburg
Subscribe to:
Posts (Atom)